Lymphomas occur with a greatly increased frequency among immunocompromised individuals regardless of whether the immunodeficiency is congenital, acquired as a result of HIV infection or iatrogenic as a result of anti-rejection therapy in allograft recipients. This article focuses on the differences in clinical management of these lymphomas.